Cargando…

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis

OBJECTIVE: To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, CENTRAL, MEDLI...

Descripción completa

Detalles Bibliográficos
Autores principales: Sazali, Suhairul, Badrin, Salziyan, Norhayati, Mohd Noor, Idris, Nur Suhaila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786797/
https://www.ncbi.nlm.nih.gov/pubmed/33402403
http://dx.doi.org/10.1136/bmjopen-2020-039358
_version_ 1783632705833926656
author Sazali, Suhairul
Badrin, Salziyan
Norhayati, Mohd Noor
Idris, Nur Suhaila
author_facet Sazali, Suhairul
Badrin, Salziyan
Norhayati, Mohd Noor
Idris, Nur Suhaila
author_sort Sazali, Suhairul
collection PubMed
description OBJECTIVE: To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019. STUDY SELECTION: All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded. DATA SYNTHESIS: Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I(2) statistic. The treatment effect for dichotomous outcomes were using risk ratios and risk difference, and for continuous outcomes, mean differences (MDs) or standardised mean difference; both with 95% CIs were used. Subgroup analyses were carried out for dosage of CoQ10 and if CoQ10 combined with another supplementation. Sensitivity analysis was used to investigate the impact risk of bias for sequence generation and allocation concealment of included studies. RESULTS: Six studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: −0.19; 95% CI: −0.27 to −0.11; random effects; I(2) statistic=0%; p<0.00001). CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: −1.52; 95% CI: −2.40 to −0.65; random effects; I(2) statistic=0%; p<0.001). CONCLUSION: CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack. PROSPERO REGISTRATION NUMBER: CRD42019126127.
format Online
Article
Text
id pubmed-7786797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77867972021-01-14 Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis Sazali, Suhairul Badrin, Salziyan Norhayati, Mohd Noor Idris, Nur Suhaila BMJ Open Neurology OBJECTIVE: To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019. STUDY SELECTION: All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded. DATA SYNTHESIS: Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I(2) statistic. The treatment effect for dichotomous outcomes were using risk ratios and risk difference, and for continuous outcomes, mean differences (MDs) or standardised mean difference; both with 95% CIs were used. Subgroup analyses were carried out for dosage of CoQ10 and if CoQ10 combined with another supplementation. Sensitivity analysis was used to investigate the impact risk of bias for sequence generation and allocation concealment of included studies. RESULTS: Six studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: −0.19; 95% CI: −0.27 to −0.11; random effects; I(2) statistic=0%; p<0.00001). CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: −1.52; 95% CI: −2.40 to −0.65; random effects; I(2) statistic=0%; p<0.001). CONCLUSION: CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack. PROSPERO REGISTRATION NUMBER: CRD42019126127. BMJ Publishing Group 2021-01-05 /pmc/articles/PMC7786797/ /pubmed/33402403 http://dx.doi.org/10.1136/bmjopen-2020-039358 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Neurology
Sazali, Suhairul
Badrin, Salziyan
Norhayati, Mohd Noor
Idris, Nur Suhaila
Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title_full Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title_fullStr Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title_full_unstemmed Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title_short Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
title_sort coenzyme q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786797/
https://www.ncbi.nlm.nih.gov/pubmed/33402403
http://dx.doi.org/10.1136/bmjopen-2020-039358
work_keys_str_mv AT sazalisuhairul coenzymeq10supplementationforprophylaxisinadultpatientswithmigraineametaanalysis
AT badrinsalziyan coenzymeq10supplementationforprophylaxisinadultpatientswithmigraineametaanalysis
AT norhayatimohdnoor coenzymeq10supplementationforprophylaxisinadultpatientswithmigraineametaanalysis
AT idrisnursuhaila coenzymeq10supplementationforprophylaxisinadultpatientswithmigraineametaanalysis